Skip to main content
Gujarat Themis Biosyn Ltd. logo

Gujarat Themis Biosyn Ltd. — Investor Relations & Filings

Ticker · GUJTHEM ISIN · INE942C01045 LEI · 3358009IT99XRO254Q79 BSE.NS Manufacturing
Open in API
Filings indexed 694 across all filing types
Latest filing 2026-05-25 Investor Presentation
Country IN India
Listing BSE.NS GUJTHEM

About Gujarat Themis Biosyn Ltd.

https://www.gtbl.in

Gujarat Themis Biosyn Ltd. specializes in the manufacture of active pharmaceutical ingredients and intermediates through advanced fermentation technology. The company focuses on the production of fermentation-based bulk drugs, with a primary product portfolio that includes Rifampicin intermediates and Lovastatin. Utilizing large-scale fermentation processes, the organization engages in strain improvement and media optimization to enhance yield and efficiency. The company operates a dedicated manufacturing facility equipped for complex biotechnological processes. Through technical collaborations with international entities, it has integrated specialized expertise in fermentation science to support the development of high-purity chemical compounds. Its operations are centered on providing essential building blocks for various therapeutic applications, maintaining a focus on technical precision and process-driven manufacturing excellence.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 92% confidence The document is a slide-based presentation titled “Investor Presentation” for Q4 & FY2025-26, submitted under SEBI Listing Regulation 30 to the stock exchanges. It contains forward-looking statements, financial highlights, management commentary, deal snapshots, and strategic outlook—features characteristic of an investor presentation deck rather than a standalone earnings release or formal report. It does not serve as a transcript, audit report, or proxy statement, so it fits the “Investor Presentation” category.
2026-05-25 English
Please refer to the attachment.
Investor Presentation Classification · 92% confidence The document is a detailed slide‐style presentation entitled “Investor Presentation” for Q4 & FY2025-26, containing a disclaimer, management commentary, business overview, strategic acquisitions, and multi‐period financial tables and charts. It was submitted under SEBI LODR Regulation 30 specifically as an Investor Presentation. Therefore, it fits the “Investor Presentation” category (IP).
2026-05-25 English
Please refer to the attachment
Regulatory Filings Classification · 85% confidence The document is an official disclosure under SEBI Listing Regulations (Regulation 30) announcing the outcome of a board meeting. It contains items such as approval of audited financial results for quarter and year ended March 31, 2026 (with auditor’s report attached), dividend recommendation, cost auditor appointment, and preferential issue committee formation. This is a regulatory announcement filed with stock exchanges rather than the full annual report or a press‐style earnings release. It falls squarely into the general regulatory filings category.
2026-05-25 English
Outcome of Board Meeting
Regulatory Filings Classification · 85% confidence The document is an official corporate announcement filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to stock exchanges (BSE & NSE). It discloses the outcome of a Board meeting (approval of audited results, dividend recommendation, auditor appointment, preferential issue proposal) and includes the statutory auditor’s report. It is not a standalone Annual Report (10-K) nor a simple dividend notice or proxy statement, and it is not merely a press release of key highlights (ER) but rather a compliance/regulatory filing. Therefore it best fits the “Regulatory Filings” (RNS) category as a general compliance announcement.
2026-05-25 English
The Board of Directors at its meeting held today, have inter alia, transacted the following items of business and taken the decisions as under: 1. Approved the Audited Financial Results ....
Interim / Quarterly Report Classification · 85% confidence The document is an “Outcome of Board Meeting” under SEBI Listing Regulations 2015 which (1) approves and attaches the audited financial results (including balance sheet and cash flow statements) for the quarter and year ended March 31, 2026, and (2) includes the independent auditor’s report. It contains actual financial statements for a quarter (and year‐to‐date) rather than just highlights or a link to a report. This matches a comprehensive interim/quarterly report filing (IR) rather than an earnings release (ER) or annual report (10‐K). FY 2026
2026-05-25 English
Investor Presentation
Investor Presentation Classification · 93% confidence The document is a presentation titled “Investor Presentation” submitted under SEBI Listing Regulations, containing strategic rationale, transaction details, synergies, and company background. It is clearly an investor presentation for the acquisition of MicroBiopharm Japan, fitting the definition of an Investor Presentation (IP).
2026-05-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.